Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 61

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 61
---
angement, (xiii) the treatment of the holders of Incentive Securities, (xiv) the ability of the Company’s shareholders to dissent in respect of the Arrangement, (xv) the equal treatment of Shareholders under the terms of the
Agreement, (xvi) advice from management and its legal and financial advisors; and (xvii) the opinion of Leerink Partners dated November 14, 2025 that, as of such date and based upon and subject to the various assumptions made, and the
qualifications and limitations upon the review undertaken by Leerink Partners in preparing its opinion, the cash consideration to be received by the Shareholders (other than holders of Excluded Shares) pursuant to the Arrangement is fair, from a
financial point of view, to the Shareholders, the Transaction Committee unanimously determined that the Consideration to be received by the Shareholders pursuant to the Arrangement is fair, from a financial point of view, to the Shareholders, that
the Arrangement is in the best interests of the Company, and unanimously recommended to the Board that it approve the Agreement and recommend that the Shareholders vote in favour of the Arrangement Resolution.

Immediately after the Transaction Committee meeting on November 14, 2025, the Board held a meeting attended by all members of the Board,
also attended by members of management and representatives of Stikeman, Cooley and Leerink Partners. Following additional discussion and consideration of the transaction and the materials that had previously been circulated to the Board (including
the factors described below under the heading “Reasons for Arrangement”), all disinterested members of the Board unanimously, after taking into consideration, among other things, the factors enumerated in the preceding paragraph
and the unanimous recommendation of the Transaction Committee, concluded that the Arrangement is in the best interests of the Company and approved the Arrangement and authorized its submission to the Shareholders.

Later, on the evening of November 14, 2025, following the Board’s approval of the Agreement (including the form of the CVR
Agreement), and the transactions, the Company, Parent, and XRC executed and delivered the Agreement (which included as an exhibit the form of the CVR Agreement).

After the close of trading on Nasdaq on November 14, 2025, the Company issued a press release announcing the execution of the Agreement.

Prior to the announcement of the Arrangement, the Company contacted certain shareholders of the Company, namely entities affiliated with
BVF Partners L.P.,